AKT1 and breast carcinoma: To elucidate mechanisms of resistance to PI3Kβ (AZD8186) and AKT (capivasertib) inhibitors in PTEN-deficient breast cancer, we performed genome-wide CRISPR knockout screens in three breast cancer (BC) cell lines with loss-of-function mutations in PTEN (Fig. 1A).